News – Page 1118 – Endpoints News

Alexion's Hantson poaches Biogen CFO Clancy as buzz of a looming pipeline shakeup heats up

8 years ago

Top JPMorgan investment banker brings his talents — and connections — to the biotech startup crew on board ...

8 years ago

Rising Penn star Saar Gill gets funding for a next-gen CAR-T startup, adding a new weapon to the mix

8 years ago

Abbvie, Principia join forces on immunoproteasome inhibitors; Scripps develops heroin vaccine, FDA fast tracks NGF ...

8 years ago

Harvard researchers hope to bridge the protein gap with new institute

8 years ago

Buyout Buzz: Sanofi, Gilead rumors keep the fire burning under a boiling Tesaro buyout story

8 years ago

pSivida lines up EMA, FDA applications for eye drug/device as 2nd PhIII delivers positive data

8 years ago

J&J boasts improved cardio safety with SGLT2 franchise drug Invokana

8 years ago

Acceleron scraps dalantercept after it flunks a PhII test for kidney cancer

8 years ago

Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths

8 years ago

Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory

8 years ago

Seres grabs $20M on PhIII microbiome launch; Gilead submits NDA; Alkermes begins Phase IIIb study

8 years ago

Little Dragonfly bursts onto the I/O scene with a $33M Celgene deal and some of the biggest names in biotech

8 years ago

Coherus craters after Amgen wins reprieve on Neulasta knockoff — FDA rejects marketing application

8 years ago

AstraZeneca punts NASH drug from an ailing Regulus as their lead program goes under for the last time

8 years ago

Seres grabs $20M on PhIII microbiome launch

8 years ago

With an FDA decision looming, Flexion touts new data spotlighting a safety edge for osteoarthritis drug

8 years ago

Merck, Pfizer make their PhIII case for an SGLT2 latecomer to the blockbuster showdown in diabetes

8 years ago

Eli Lilly posts promising PhIII migraine results, but settles into the pack in the last leg of the race to the FDA

8 years ago

Trial observers say ‘game over’ for XBiotech's failed PhIII cancer study, the latest in a long line of setbacks

8 years ago

Peer Review: J&J woos Merck’s Mathai Mammen to helm of pharma R&D; Merrimack, Bayer, and Axovant expand leadership ...

8 years ago

8 stars: A look back at ASCO spotlights the top cancer drugs to watch, and 1 to forget

8 years ago

Bristol-Myers shares drop; Regenera offers a lifeline to sinking Alcobra

8 years ago

So what’s star Broad investigator Feng Zhang up to now?

8 years ago

First page Previous page 1115 1116 111711181119 1120 1121 Next page Last page